EUDR – A Compliance Timebomb for the Life Sciences Industry

Regulatory Pressure by the Numbers

• €42 billion: Market exposure from regulated topical formulations

• 3 percent: Share of pharma revenue linked to impacted product categories

• 4.5 percent: Life sciences’ contribution to global GHG emissions

• 227 million tCO₂e: Total carbon impact reported by public companies, up 15 percent year-over-year

Key palm-derived ingredients such as glycerol, stearic acid, palmitic acid, and oleic acid are under scrutiny. Companies must trace origins, validate sourcing, and update product labeling accordingly.

Key Takeaways from the Report

• Palm oil derivatives are embedded across most topical categories

• Ingredient-level risk affects over 60 percent of formulations

• Market access depends on proving deforestation-free sourcing

• Compliance timelines require strategic action well before 2025

• Supply chain recalibration and reformulation are now priority areas

Strategic Actions Required

• Map EUDR-regulated commodities across product lines

• Prioritize ingredients based on sourcing origin and consumption volume

• Secure certified alternatives with functional equivalence

• Align reformulations with EU documentation standards

• Prepare for full-scope traceability and audit compliance